EUCTR2020-004427-16-AT进行中（未招募）1 期
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (PORTAL)
F. Hoffman-La Roche Ltd0 个研究点目标入组 1,035 人开始时间: 2021年12月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,035
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Previous enrollment in and completion of Study GX28228 (Ladder) or Study GR40548 (Archway), without early treatment or study discontinuation in either study (monthly intravitreal ranibizumab 0.5 mg or implant arms) OR Previous enrollment in Study WR42221 (Velodrome) and either not eligible to be randomized in Study WR42221 at Week 24 or completed the study (from the Q24W or Q36W arm)
- •- Ability and willingness to undertake all scheduled visits and assessments
- •- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures during the treatment period and for at least 3 months after the last intravitreal injection of ranibizumab or 1 year after the last implant refill-exchange of ranibizumab
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 145
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 890
排除标准
- •- Pregnant or breastfeeding, or intending to become pregnant during the treatment period and for at least 3 monthsafter the final intravitreal injection of ranibizumab or 1 year after the last implant refill-exchange of ranibizumab
- •- History of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, that might affect interpretation of the results of the study or that renders the patient at high risk for treatment complications
- •- History of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or that renders the patient at high risk of treatment complications
- •- Requirement for continuous use of any medications or treatments indicated in the Prohibited Therapy
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate long-term safety and tolerability of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (Omaspect)EUCTR2016-000423-13-DKF. Hoffmann-La Roche Ltd1,800
进行中（未招募）
1 期
A study to evaluate long-term safety and tolerability of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (Omaspect)EUCTR2016-000423-13-DEF. Hoffmann-La Roche Ltd1,800
进行中（未招募）
1 期
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular EdemaDiabetic Macular Edema (DME)MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2020-000402-29-GBF.Hoffmann La-Roche Ltd1,800
进行中（未招募）
1 期
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular EdemaEUCTR2020-000402-29-CZF.Hoffmann La-Roche Ltd1,800
进行中（未招募）
1 期
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular EdemaDiabetic Macular Edema (DME)MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853EUCTR2020-000402-29-PTF.Hoffmann La-Roche Ltd1,800